DUBLIN, Ireland and TORONTO, Canada, Nov. 29, 2022 — Avectas, a cell engineering technology business and CCRM, with its subsidiary OmniaBio Inc., a CDMO that enables the development of cell therapies and associated technologies for clinical and commercial manufacture, have announced an expansion of their collaboration, to enable the development of gene-edited induced pluripotent stem cells (iPSCs) using Avectas’ non-viral cell engineering platform, SOLUPORE®. [Read more…]
Sponsored Content: Press releases may be published as paid or sponsored content. The issuers of these press releases are solely responsible for their content. BioInformant is not responsible for the accuracy or claims made in these announcements and does not endorse the views expressed by their issuers.
Caribou Biosciences Granted FDA RMAT and Fast Track Designations for CB-010, an Allogeneic Anti-CD19 CAR-T Cell Therapy
RMAT and Fast Track designations follow CB-010’s durable complete responses at dose level 1 in the ANTLER Phase 1 trial
CB-010 is the 1st allogeneic CAR-T cell therapy in the clinic with a PD-1 knockout
Therapeutic Solutions International Launches Spin-Off Breathe Biologics Aimed at Curing COPD
Phase III Clinical Trial Stem Cell Company Aims to Fast Forward Regenerative Solutions to Dreaded Lung Disease
November 9, 2022, ELK CITY, Idaho — Therapeutic Solutions International (TSOI) announced the launching of a spin-off company, Breathe Biologics, Inc., to commercialize technologies in the area of COPD. [Read more…]
Pan Cancer T and NecstGen Collaborate to Accelerate Novel TCR-T Therapies into Clinical Development
Rotterdam and Leiden, the Netherlands, November 23, 2022 – Pan Cancer T B.V., a biotech spin-off from Erasmus MC dedicated to the discovery and development of novel second generation TCR-T therapies against solid tumors, and NecstGen B.V., The Netherlands Center for the Clinical Advancement of Stem Cells and Gene Therapy, today announced a partnership to advance Pan Cancer T’s innovative therapies into the clinic. Under the agreement, NecstGen will provide process and analytical development capabilities. [Read more…]
Steakholder Foods® Successfully Produced Porcine Fat Cells Differentiated from iPSC for Cultivated Pork Products
This will enhance the company’s ability to produce high-quality structured pork products at scale.
REHOVOT, Israel, Nov. 10, 2022 — Steakholder Foods Ltd. (NASDAQ: STKH), (formerly MeaTech 3D: MITC), an international deep-tech food company at the forefront of the cultured meat industry, today announced that it has successfully differentiated porcine fat cells from its induced pluripotent stem cell line. [Read more…]
- « Previous Page
- 1
- …
- 54
- 55
- 56
- 57
- 58
- …
- 118
- Next Page »